{"url_path":"/sec/bcax/8-k/2026-06-10/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-10","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-042176-index.html","accession_number":"0001628280-26-042176","cik":"0002023658","ticker":"BCAX","issuer_name":"Bicara Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-042176-index.html","primary_entity_key":"0002023658","primary_entity_name":"Bicara Therapeutics Inc."},"word_count":314,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn June 9, 2026, Bicara Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2026. Of the 65,600,370 shares of the Company’s common stock outstanding as of the record date, 55,924,987 shares, or approximately 85.25%, were present or represented at the Annual Meeting. Set forth below are the final results of the matters submitted for a vote of the stockholders at the Annual Meeting.\n\nProposal 1: Election of Directors\n\nThe Company’s stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company’s 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows:\n\nDirector\n\nVotes For\n\nVotes Withheld\n\nBroker Non-Votes\n\nChristopher Bowden, M.D.\n\n48,558,710\n\n5,145,418\n\n2,220,859\n\nCarolyn Ng, Ph.D.\n\n47,431,269\n\n6,272,859\n\n2,220,859\n\nProposal 2: Ratification of KPMG LLP\n\nThe Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:\n\nVotes For\n\nVotes Against\n\nVotes Abstaining\n\nRatification of appointment of KPMG LLP\n\n55,914,602\n\n8,815\n\n1,570\n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nBicara Therapeutics Inc.\n\nDate: June 10, 2026\n\nBy:\n\n /s/ Claire Mazumdar\n\nName:\n\nClaire Mazumdar, Ph.D.\n\nTitle:\n\nChief Executive Officer"}